Skip to content
value.today
Inotek Pharmaceuticals Corp. logo

Inotek Pharmaceuticals Corp.

Total raised
$24 M
1 round on record
Latest round
$24 M
Jun 2010
First round on record
Jun 2010
Today
Went public
See the company page

Inotek Pharmaceuticals Corp. is listed today as Rocket Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Inotek Pharmaceuticals Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2010$24 MNo. 1$10 to $50 million

Inotek Pharmaceuticals Corp.: Raise no. 1, Jun 2010

Investors in this round

11 investors had bought by the notice of Jul 19, 2011: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Inotek Pharmaceuticals Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James G. Ham, III · Executive Officer · Chief Financial Officer
  • Paul G. Howes · Executive Officer, Director · President & Chief Executive Officer
  • Rudolf A. Baumgartner, MD · Executive Officer · Executive Vice President, Chief Medical Officer
  • William K. McVicar, Ph.D. · Executive Officer · Executive Vice President, Chief Scientific Offier
  • "Argeris (""Jerry"")" N. Karabelas, PhD · Director
  • Atul N. Saran · Director
  • Ittai N. Harel · Director
  • John N. Leaman · Director
  • Martin N. Vogelbaum · Director
  • Michael D. Loberg, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul G. Howes, President & CEO. Newest notice filed Jul 19, 2011 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Inotek Pharmaceuticals Corp. chose not to state its revenue in its newest notice of a funding round (Jul 2011).

    SEC Form D · Jul 2011

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2011

Products and services#

No products or services of Inotek Pharmaceuticals Corp. are on record.

Investors#

24 named in official filings. Open an investor to see everything it has backed.

Investors in Inotek Pharmaceuticals Corp.
InvestorKindAmountRoundRoleSource
Care Capital III LLCFund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital II LLCFund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital Investments III L.P.Fund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital Investments II LPFund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital Offshore Investments III LPFund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital Offshore Investments II LPFund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Devon Park Associates, LLCOthernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Devon Park Associates, L.P.Fund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Devon Park Bioventures LPVenture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
MedImmune Ventures, Inc.Venture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Paul G. HowesPersonnot statednot statedHeld Series X preferred stock, director (Form 3, 2015)SEC Form 3
Pitango G.C. Capital Holdings Ltd.Fund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Pitango V.C. Fund IV, L.P.Fund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Pitango Venture Capital Fund IV, L.P.Venture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Pitango Venture Capital Principals Fund IV, L.P.Venture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rho Capital Partners Verwaltungs GmbhFund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rho Management Ventures IV LLCVenture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rho Ventures IV-A, L.P.Venture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rho Ventures IV Gmbh & Co Beteiligungs KGVenture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rho Ventures IV Holdings LLCVenture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rho Ventures IV LPVenture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rho Ventures IV QP LPVenture capitalnot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Rudolph BaumgartnerPersonnot statednot statedHeld Series X preferred stock (Form 3, 2015)SEC Form 3
William K. McVicarPersonnot statednot statedHeld Series X preferred stock (Form 3, 2015)SEC Form 3

Largest shareholders today

Institutions holding Rocket Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Inotek Pharmaceuticals Corp.
NameRoleNamed in
James G. Ham, IIIChief Financial OfficerJul 2011
Paul G. HowesPresident & Chief Executive OfficerJul 2011
Rudolf A. Baumgartner, MDExecutive Vice President, Chief Medical OfficerJul 2011
William K. McVicar, Ph.D.Executive Vice President, Chief Scientific OffierJul 2011
"Argeris (""Jerry"")" N. Karabelas, PhDDirectorJul 2011
Atul N. SaranDirectorJul 2011
Ittai N. HarelDirectorJul 2011
John N. LeamanDirectorJul 2011
Martin N. VogelbaumDirectorJul 2011
Michael D. Loberg, PhDDirectorJul 2011
Paul G. HowesPresident & Chief Executive OfficerJul 2011
Ittai Flanagan HarelDirectorJun 2010
John Flanagan LeamanDirectorJun 2010
Maggie Flanagan LeFlore, PhDDirectorJun 2010

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.